Novartis (NVS) to Post Earnings on Tuesday

Novartis (NYSE:NVS) is anticipated to post its Q2 2026 results before the market opens on Tuesday, July 21st. Analysts expect the company to post earnings of $2.17 per share and revenue of $14.0665 billion for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 21, 2026 at 11:40 AM ET.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.11 by ($0.12). The company had revenue of $13.52 billion for the quarter, compared to analysts’ expectations of $13.44 billion. Novartis had a return on equity of 38.82% and a net margin of 24.87%.The company’s revenue for the quarter was down .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.28 EPS. On average, analysts expect Novartis to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Novartis Trading Up 0.7%

NYSE:NVS opened at $153.78 on Friday. Novartis has a 12 month low of $112.34 and a 12 month high of $170.46. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. The firm’s 50 day moving average is $151.41 and its 200 day moving average is $151.61. The stock has a market capitalization of $293.44 billion, a PE ratio of 22.03, a price-to-earnings-growth ratio of 2.65 and a beta of 0.45.

Institutional Trading of Novartis

A number of institutional investors have recently modified their holdings of NVS. Brighton Jones LLC grew its position in shares of Novartis by 76.5% in the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after purchasing an additional 2,666 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in Novartis by 48.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock worth $963,000 after purchasing an additional 2,581 shares in the last quarter. Schnieders Capital Management LLC. bought a new position in Novartis in the 2nd quarter worth about $202,000. Crawford Investment Counsel Inc. bought a new position in Novartis in the 4th quarter worth about $202,000. Finally, McMillan Office Inc. purchased a new position in Novartis during the 4th quarter valued at about $147,000. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on NVS shares. Morgan Stanley raised their target price on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research report on Thursday, March 26th. Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.